Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.68 | N/A | -0.41% |
management commentary, guidance changes, and full analysis available with Pro.
| -0.41% |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They are focused on adapting strategies to navigate these challenges.
Management highlighted ongoing challenges in the market.
They emphasized the need for strategic adjustments moving forward.
Bristol Myers Squibb's earnings report indicates a slight miss on EPS, which contributed to a 3.97% decline in stock price. Investors may be reacting to management's cautious tone regarding market challenges. The lack of guidance could lead to uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ASTRAZENECA PLC
Feb 2, 2018